Merck – pharmaceutical daily

August 23, 2023 Off

AiCuris Received 30 Million Euros Milestone Payment from Licensing Partner MSD Following U.S. FDA Approval of PREVYMIS

AiCuris Anti-infective Cures AG has received milestone payments in the amount of EUR €30 million from its licensing partner MSD (Merck) after the U.S. FDA’s approval for first-in-class antiviral agent PREVYMIS® in a new indication – the prophylaxis of CMV disease after kidney transplant in Donor CMV-seropositive/Recipient CMV-seronegative patients.

October 12, 2022 Off

Merck and Moderna take option by Merck for joint development dealing of investigational personalized cancer vaccine

By Dino Mustafić

Merck has exercised its option to jointly develop and commercialize personalized cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing Collaboration and License Agreement.

December 17, 2021 Off

Merck and Ridgeback Announce Publication of Phase 3 Study of Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, in the New England Journal of Medicine

By BusinessWire

Molnupiravir is authorized in the United Kingdom as the first oral antiviral for the treatment of mild to moderate COVID-19 in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk factor for developing severe illness.

October 5, 2021 Off

Merck to seek emergency use authorization for Molnupiravir, oral antiviral medicine for COVID-19

By Dino Mustafić

The drug maker Merck said it plans to seek emergency use authorization in the U.S. as soon as possible and to submit applications to regulatory agencies worldwide for Molnupiravir, which could be the first oral antiviral medicine for COVID-19.

July 19, 2021 Off

Merck Announces U.S. FDA Approval of VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for the Prevention of Invasive Pneumococcal Disease in Adults 18 Years and Older Caused by 15 Serotypes

By BusinessWire

Clinical Data Supporting Approval Demonstrated Non-Inferior Immune Responses for the Serotypes Shared with PCV13 (1, 3, 4, 5, 6A, 6B,…

July 12, 2021 Off

Interim Results from Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19, Presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID)

By BusinessWire

KENILWORTH, N.J. & MIAMI–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics…

June 17, 2020 Off

Merck and Pfizer’s SGLT2 Inhibitor STEGLATROTM (ertugliflozin) Meets Primary Endpoint in VERTIS CV Trial for Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

By BusinessWire

Results Presented at the American Diabetes Association’s Virtual 80th Scientific Sessions KENILWORTH, N.J. & NEW YORK–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK),…

June 5, 2020 Off

FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)

By BusinessWire

RECARBRIO is Indicated to Treat Multiple Infections Caused by Susceptible Gram-Negative Bacteria in Adults KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK),…

May 28, 2020 Off

RefleXion Announces Clinical Collaboration to Evaluate Biology-guided Radiotherapy With Merck’s Keytruda for Certain Late-Stage Cancers

By BusinessWire

RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy for treating all stages of cancer, today announced a clinical collaboration with Merck.

May 26, 2020 Off

Merck Announces Third-Quarter 2020 Dividend

By BusinessWire

KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board…